Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Executive Summary

Allergan has two oral CGRP inhibitors – the only small molecules in the drug class in the clinic – but anti-CGRP biologics are likely to hit the market first. However, an effective oral product from a company that’s already marketing a migraine drug – Botox – could be an overlooked contender.

Advertisement

Related Content

Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most
Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study
Biohaven Posts Positive Migraine Results, But Investors Are Wary
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Pharma Q3 Results Preview: Pfizer, Allergan, Sanofi, Teva & AstraZeneca
Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Allergan Confident About Continued Growth, Swats Down Competition Concerns
Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success
Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal
Allergan migraine portfolio grows with Merck CGRP antagonists

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel